Zentalis Pharmaceuticals, Inc. (ZNTL) — Financial statements
Income statement, balance sheet, and cash flow for Zentalis Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00↓100.0% | 67 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00↓100.0% | 67 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 107↓36.0% | 168↓28.7% | 235↑36.1% | 173↓1.6% | 176 | |
| General & Administrative Expenses | 38↓56.7% | 87↑46.7% | 59↑8.9% | 55↑33.2% | 41 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 38↓56.7% | 87↑46.7% | 59↑8.9% | 55↑33.2% | 41 | |
| Other Expenses | 8↑108.7% | 4↓24.6% | 5 | 0.00 | 0.00 | |
| Operating Expenses | 153↓40.9% | 259↓13.7% | 300↑31.8% | 227↑5.0% | 217 | |
| Total Costs & Expenses | 153↓40.9% | 259↓13.7% | 300↑31.8% | 227↑5.0% | 217 | |
| Operating Results | ||||||
| Operating Income | -153↑20.1% | -191↑36.2% | -300↓31.8% | -227↓5.0% | -217 | |
| Depreciation & Amortization | 0.74↓42.7% | 1↓7.2% | 1↓2.6% | 1↑162.1% | 0.54 | |
| EBITDA | -144↑22.5% | -186↑24.8% | -248↓9.6% | -226↓9.0% | -207 | |
| EBIT | -145↑22.6% | -187↑24.7% | -249↓9.5% | -227↓9.4% | -208 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00↑100.0% | -3 | 0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00↓100.0% | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 3 | 0.00 | |
| Non-Operating Income | -8↓108.7% | -4↑92.6% | -51 | 0.00↑100.0% | -9 | |
| Other Income / Expenses | 16↓36.5% | 26↑286.2% | 7↑164.1% | -10↓120.5% | 50 | |
| Income Before Tax | -137↑17.5% | -166↑43.4% | -293↓23.3% | -238↓42.8% | -166 | |
| Income Tax Expense | 0.44↑149.7% | 0.18↑129.5% | -0.60↓28.1% | -0.47↓57.9% | -0.30 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -137↑17.4% | -166↑43.3% | -292↓23.3% | -237↓42.8% | -166 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -137↑17.4% | -166↑43.2% | -292↓23.4% | -237↓49.2% | -159 | |
| Bottom-Line Net Income | -137↑17.4% | -166↑43.2% | -292↓23.4% | -237↓49.2% | -159 | |
| EPS (Basic) | -1.91↑18.0% | -2.33↑47.9% | -4.47↑0.2% | -4.48↓20.4% | -3.72 | |
| EPS (Diluted) | -1.91↑18.0% | -2.33↑47.9% | -4.47↑0.2% | -4.48↓20.4% | -3.72 | |
| Weighted Average Shares | 72↑1.1% | 71↑8.7% | 65↑23.7% | 53↑23.8% | 43 | |
| Weighted Average Diluted Shares | 72↑1.1% | 71↑8.7% | 65↑23.7% | 53↑23.8% | 43 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.